Divergence in CD19-mediated signaling unfolds intraclonal diversity in chronic lymphocytic leukemia, which correlates with disease progression

Journal of Immunology

Volumn 190, Issue 2, 2013, Pages 784-793

  Herishanu, Yair ^a   Kay, Sigi ^a   Dezorella, Nili ^a,b   Baron, Shoshana ^a   Hazan Halevy, Inbal ^a   Porat, Ziv ^c   Trestman, Svetlana ^a   Perry, Chava ^a   Braunstein, Rony ^a   Deutsch, Varda ^a   Polliack, Aaron ^a   Naparstek, Elizabeth ^a,b   Katz, Ben Zion ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; IMMUNOGLOBULIN M; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RITUXIMAB;

ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER GROWTH; CD19 GENE; CELL AGGREGATION; CELL FRACTIONATION; CELL SUBPOPULATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSTIMULATION; LEUKEMIA CELL; ONCOGENE C MYC; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GENE;

EID: 84872187163     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200615     Document Type: Article

References (49)

1. Chiorazzi, N., K. R. Rai, and M. Ferrarini. 2005. Chronic lymphocytic leukemia. N. Engl. J. Med. 352: 804-815.
2. Caligaris-Cappio, F., and T. J. Hamblin. 1999. B-cell chronic lymphocytic leukemia: a bird of a different feather. J. Clin. Oncol. 17: 399-408.
3. Chen, L., G. Widhopf, L. Huynh, L. Rassenti, K. R. Rai, A. Weiss, and T. J. Kipps. 2002. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100: 4609-4614.
4. Richardson, S. J., C. Matthews, M. A. Catherwood, H. D. Alexander, B. S. Carey, J. Farrugia, A. Gardiner, S. Mould, D. Oscier, J. A. Copplestone, and A. G. Prentice. 2006. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107: 3584-3592.
5. Deaglio, S., T. Vaisitti, S. Aydin, L. Bergui, G. D'Arena, L. Bonello, P. Omedé, M. Scatolini, O. Jaksic, G. Chiorino, et al. 2007. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 110: 4012-4021.
6. Chiorazzi, N., and M. Ferrarini. 2003. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21: 841-894.
7. Chen, L., L. Huynh, J. Apgar, L. Tang, L. Rassenti, A. Weiss, and T. J. Kipps. 2008. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 111: 2685-2692.
8. Crespo, M., F. Bosch, N. Villamor, B. Bellosillo, D. Colomer, M. Rozman, S. Marcé, A. López-Guillermo, E. Campo, and E. Montserrat. 2003. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348: 1764-1775.
9. Hallek, M., K. Fischer, G. Fingerle-Rowson, A. M. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. von Grünhagen, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. 2010. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376: 1164-1174.
10. Friedberg, J. W., J. Sharman, J. Sweetenham, P. B. Johnston, J. M. Vose, A. Lacasce, J. Schaefer-Cutillo, S. De Vos, R. Sinha, J. P. Leonard, et al. 2010. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578-2585.
11. Matutes, E., and A. Polliack. 2000. Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev. Clin. Exp. Hematol. 4: 22-47.
12. H gene diversification. J. Exp. Med. 196: 629-639.
13. Calissano, C., R. N. Damle, G. Hayes, E. J. Murphy, M. K. Hellerstein, C. Moreno, C. Sison, M. S. Kaufman, J. E. Kolitz, S. L. Allen, et al. 2009. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 114: 4832-4842.
14. Cerutti, A., H. Zan, E. C. Kim, S. Shah, E. J. Schattner, A. Schaffer, and P. Casali. 2002. Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells. J. Immunol. 169: 6594-6603.
15. Nadav-Dagan, L., and B. Z. Katz. 2011. Malignant B-cell intra-clonal diversification: following the yarn in the labyrinth. Leuk. Lymphoma 52: 2050-2056.
16. + tumor cells. Clin. Cancer Res. 14: 4650-4657.
17. Ausili, A., A. Torrecillas, F. J. Aranda, F. Mollinedo, C. Gajate, S. Corbalán-García, A. de Godos, and J. C. Gómez- Fernández. 2008. Edelfosine is incorporated into rafts and alters their organization. J. Phys. Chem. B 112: 11643-11654.
18. Mollinedo, F., J. de la Iglesia-Vicente, C. Gajate, A. Estella-Hermoso de Mendoza, J. A. Villa-Pulgarin, M. de Frias, G. Roué, J. Gil, D. Colomer, M. A. Campanero, and M. J. Blanco-Prieto. 2010. In vitro and In vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin. Cancer Res. 16: 2046-2054.
19. Gajate, C., F. Gonzalez-Camacho, and F. Mollinedo. 2009. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem. Biophys. Res. Commun. 380: 780-784.
20. König, A., G. K. Schwartz, R. M. Mohammad, A. Al-Katib, and J. L. Gabrilove. 1997. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90: 4307-4312.
21. Jones, D. T., E. Addison, J. M. North, M. W. Lowdell, A. V. Hoffbrand, A. B. Mehta, K. Ganeshaguru, N. I. Folarin, and R. G. Wickremasinghe. 2004. Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. Blood 103: 1855-1861.
22. Mone, A. P., C. Cheney, A. L. Banks, S. Tridandapani, N. Mehter, S. Guster, T. Lin, C. F. Eisenbeis, D. C. Young, and J. C. Byrd. 2006. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 20: 272-279.
23. Buchner, M., S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholomé, M. Burger, N. Chevalier, L. Vallat, J. Timmer, J. G. Gribben, et al. 2009. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 69: 5424-5432.
24. Matutes, E., A. Attygalle, A. Wotherspoon, and D. Catovsky. 2010. Diagnostic issues in chronic lymphocytic leukaemia (CLL). Best Pract. Res. Clin. Haematol. 23: 3-20.
25. Vallhov, H., C. Gutzeit, S. M. Johansson, N. Nagy, M. Paul, Q. Li, S. Friend, T. C. George, E. Klein, A. Scheynius, and S. Gabrielsson. 2011. Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J. Immunol. 186: 73-82.
26. Herishanu, Y., P. Pérez-Galán, D. Liu, A. Biancotto, S. Pittaluga, B. Vire, F. Gibellini, N. Njuguna, E. Lee, L. Stennett, et al. 2011. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117: 563-574.
27. Smith, S. H., K. P. Rigley, and R. E. Callard. 1991. Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-1-dependent and -independent mechanisms. Immunology 73: 293-297.
28. Kansas, G. S., and T. F. Tedder. 1991. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J. Immunol. 147: 4094-4102.
29. Behr, S. I., D. Korinth, and F. Schriever. 1998. Differential adhesion pattern of B cell chronic lymphocytic leukemia cells. Leukemia 12: 71-77.
30. Kheirallah, S., P. Caron, E. Gross, A. Quillet-Mary, J. Bertrand-Michel, J.-J. Fournié, G. Laurent, and C. Bezombes. 2010. Rituximab inhibits B-cell receptor signaling. Blood 115: 985-994.
31. Bradbury, L. E., G. S. Kansas, S. Levy, R. L. Evans, and T. F. Tedder. 1992. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 149: 2841-2850.
32. 2-adrenergic receptor-induced regulation of B7-2 (CD86) expression in B cells. J. Immunol. 168: 6314-6322.
33. Gobessi, S., L. Laurenti, P. G. Longo, S. Sica, G. Leone, and D. G. Efremov. 2007. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 109: 2032-2039.
34. Otero, D. C., S. A. Omori, and R. C. Rickert. 2001. Cd19-dependent activation of Akt kinase in B-lymphocytes. J. Biol. Chem. 276: 1474-1478.
35. H-gene mutational status. Blood 109: 4424-4431.
36. Tedder, T. F., and C. M. Isaacs. 1989. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes: a new member of the immunoglobulin superfamily. J. Immunol. 143: 712-717.
37. Uckun, F. M., A. L. Burkhardt, L. Jarvis, X. Jun, B. Stealey, I. Dibirdik, D. E. Myers, L. Tuel-Ahlgren, and J. B. Bolen. 1993. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J. Biol. Chem. 268: 21172-21184.
38. Chalupny, N. J., S. B. Kanner, G. L. Schieven, S. F. Wee, L. K. Gilliland, A. Aruffo, and J. A. Ledbetter. 1993. Tyrosine phosphorylation of CD19 in pre-B and mature B cells. EMBO J. 12: 2691-2696.
39. Matsumoto, A. K., D. R. Martin, R. H. Carter, L. B. Klickstein, J. M. Ahearn, and D. T. Fearon. 1993. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J. Exp. Med. 178: 1407-1417.
40. Bradbury, L. E., V. S. Goldmacher, and T. F. Tedder. 1993. The CD19 signal transduction complex of B lymphocytes: deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13. J. Immunol. 151: 2915-2927.
41. Lobo, E. O., Z. Zhang, and J. E. Shively. 2009. Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner. J. Leukoc. Biol. 86: 205-218.
42. Todd, S. C., S. G. Lipps, L. Crisa, D. R. Salomon, and C. D. Tsoukas. 1996. CD81 expressed on human thymocytes mediates integrin activation and interleukin 2-dependent proliferation. J. Exp. Med. 184: 2055-2060.
43. Chung, E. Y., J. N. Psathas, D. Yu, Y. Li, M. J. Weiss, and A. Thomas-Tikhonenko. 2012. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J. Clin. Invest. 122: 2257-2266.
44. Miyamoto, S., H. Teramoto, O. A. Coso, J. S. Gutkind, P. D. Burbelo, S. K. Akiyama, and K. M. Yamada. 1995. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. J. Cell Biol. 131: 791-805.
45. Küppers, R. 2005. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer 5: 251-262.
46. Sato, S., M. Hasegawa, M. Fujimoto, T. F. Tedder, and K. Takehara. 2000. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J. Immunol. 165: 6635-6643.
47. Beum, P. V., A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor. 2006. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176: 2600-2609.
48. Beum, P. V., E. M. Peek, M. A. Lindorfer, F. J. Beurskens, P. J. Engelberts, P. W. Parren, J. G. van de Winkel, and R. P. Taylor. 2011. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J. Immunol. 187: 3438-3447.
49. Wiestner, A., A. Rosenwald, T. S. Barry, G. Wright, R. E. Davis, S. E. Henrickson, H. Zhao, R. E. Ibbotson, J. A. Orchard, Z. Davis, et al. 2003. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101: 4944-4951.